Detail akcie Trinity Bio Sp ADR online

Business Summary: Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Trinity Biotech PLC (ADR) revenues increased 8% to $61.6M. Net loss before extraordinary items decreased 15% to $31.2M. Revenues reflect Point of care segment increase of 92% to $17.4M, Ireland segment increase of 67% to $19.8M. Lower net loss reflects Americas segment loss decrease of 67% to $5.1M, Unallocated segment loss decrease of 6% to $3.4M.